REFERENCES

1. Kanglin C, Xi C, Yuhua R. Investigation analysis on initial drug injection among drug users in xichang city of sichuan province. Journal of Preventive Medicine Information 2006;22(1).
2. National Bureau of Statistics. Population indicators. NBS web site, <https://data.stats.gov.cn/easyquery.htm?cn=C01>. Accessed 13 Sep 2023.
3. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 2017;5:e1192-e1207.
4. Department of Population and Employment Statistics, National Bureau of Statistics. China population and employment statistics yearbook 2021. China Statistics Press, 2021.
5. Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A seroepidemiological study on hepatitis C in China. Zhonghua Liu Xing Bing Xue Za Zhi 2011;32:888-891.
6. CDA foundation. Polaris observatory HCV. CDA foundation, <https://cdafound.org/polaris-countries-dashboard/>. Accessed Sep 13, 2023.
7. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-176.
8. Chinese Center for Disease Control and Prevention. <https://www.chinacdc.cn/jksj/jksj01/>. Accessed Nov 10, 2024.
9. Hui Z, Lai W, Guiqiang W. Health China 2030 white paper on action to eliminate the threat of hepatitis C 2030. web site, <http://www.cphcf.org.cn/zgcb/contents/650/30644.html>. Accessed Sep 11, 2023.
10. Chinese Society of Hepatology. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 2015;23:906-923.
11. Chinese Society of Hepatology; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version). Zhonghua Gan Zang Bing Za Zhi 2019;27:962-979.
12. National Healthcare Security Administration. Notice on the inclusion of the 2019 negotiated drugs into the national basic medical insurance, work injury insurance and maternity insurance drug catalog 2019. National Healthcare Security Administration, <http://www.nhsa.gov.cn/art/2019/11/28/art_53_2057.html> Accessed Nov 13, 2022.
13. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269.
14. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960.
15. Wu J, Zhou Y, Fu X, Deng M, Zheng Y, Tian G, et al. The Burden of chronic hepatitis C in China from 2004 to 2050: An individual-based modeling study. Hepatology 2019;69:1442-1452.
16. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
17. Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y, et al. Efficacy and safety of 12-week interferon-based danoprevir regimen in patients with genotype 1 chronic hepatitis C. J Clin Transl Hepatol 2019;7:221-225.
18. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
19. Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 2019;4:127-134.
20. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. Prisons. Ann Intern Med 2016;164:84-92.
21. Feld JJ. HCV infection on-treatment viral kinetics: Do they still have a role? Clin Liver Dis (Hoboken) 2012;1:51-53.
22. United Nations. Department of economic and social AffairsPopulation division. United Nations UN web site, <https://population.un.org/wpp/downloads?folder=Standard%20Projections&group=Most%20used>. Accessed 13 Sep 2023.
23. Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY, et al. Mortality of HIV infected clients treated with methadone maintenance treatment in Yili Kazakh autonomous prefecture. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45:979-984.
24. Zhang L, Ruan YH, Jiang ZQ, Yang ZN, Liu SZ, Zhou F, et al. An 1-year prospective cohort study on mortality of injecting drug users. Zhonghua Liu Xing Bing Xue Za Zhi 2005;26:190-193.

 https://doi.org/10.3350/cmh.2024.0664

25. Janiak M, Caraballo Cortes K, Demkow U, Radkowski M. Spontaneous elimination of hepatitis C virus infection. Adv Exp Med Biol 2018;1039:45-54.
26. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431.
27. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
28. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-830.
29. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.
30. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-156.e2.
31. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-747.
32. Chinese Society of Hepatology and Chinese Society of Infectious Diseases; Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C (2022 version). Zhonghua Gan Zang Bing Za Zhi 2022;30:1332-1348.
33. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.